Hikma completes acquisition of Teligent sterile injectable assets

London, 3 February 2022 - Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces that, following its announcement on 17 January that it had agreed to acquire the Canadian assets of Teligent Inc. for $45.75 million, this transaction has now completed.

The acquisition marks Hikma's expansion into Canada and includes a portfolio of 25 sterile injectable products, three in-licenced ophthalmic products and a pipeline of seven additional products, four of which are approved by Health Canada.

Riad Mishlawi, President of Hikma Injectables, commented, "The completion of this acquisition expands Hikma's presence in the highly attractive Canadian injectables market, bringing a strong portfolio of sterile injectable products, as well as strengthening our pipeline.  We are excited to bring these important products to our Canadian customers and their patients."

- ENDS -

Enquiries:

Hikma (Investors):                           

Teneo (Press):                                                                                  

About Hikma

(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB-/stable S&P and BBB-/stable Fitch)

Hikma helps put better health within reach every day for millions of people around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,600 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com